These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15493092)

  • 1. Comment on Lambert and Hartsough (1998).
    Mick E; Biederman J; Faraone SV
    J Learn Disabil; 2000; 33(4):314; author reply 314-6. PubMed ID: 15493092
    [No Abstract]   [Full Text] [Related]  

  • 2. Childhood stimulant treatment and risk for later substance abuse.
    Fischer M; Barkley RA
    J Clin Psychiatry; 2003; 64 Suppl 11():19-23. PubMed ID: 14529326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD.
    Kantak KM; Dwoskin LP
    Pharmacol Biochem Behav; 2016 Jun; 145():24-6. PubMed ID: 27012495
    [No Abstract]   [Full Text] [Related]  

  • 4. An update on attention deficit disorder.
    Harv Ment Health Lett; 2004 May; 20(11):4-7. PubMed ID: 15153391
    [No Abstract]   [Full Text] [Related]  

  • 5. Does stimulant treatment lead to substance use disorders?
    Faraone SV; Wilens T
    J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADHD treatment and the risk of substance abuse.
    Sircy RA; Stojanoski A
    Nurse Pract; 2008 Apr; 33(4):33-6. PubMed ID: 18388552
    [No Abstract]   [Full Text] [Related]  

  • 7. What exactly are the benefits of stimulants for ADHD?
    Advokat C
    J Atten Disord; 2009 May; 12(6):495-8. PubMed ID: 19380518
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of attention deficit/hyperactivity disorder and the use of stimulants in prison. Evaluation of the risks and benefits.
    Fructuoso A
    Rev Esp Sanid Penit; 2019; 21(2):113-114. PubMed ID: 31642863
    [No Abstract]   [Full Text] [Related]  

  • 10. Attention deficit hyperactivity disorder and substance use disorders.
    Bukstein OG
    Curr Top Behav Neurosci; 2012; 9():145-72. PubMed ID: 21789746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADHD: disorder or discipline problem?
    Faraone SV; Biederman J
    Science; 2001 Feb; 291(5508):1488-9. PubMed ID: 11234074
    [No Abstract]   [Full Text] [Related]  

  • 12. Attention-deficit/hyperactivity disorder and substance abuse.
    Harstad E; Levy S;
    Pediatrics; 2014 Jul; 134(1):e293-301. PubMed ID: 24982106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulant treatment for ADHD may not increase risk of substance abuse.
    Harv Ment Health Lett; 2008 Jun; 24(12):7. PubMed ID: 18946888
    [No Abstract]   [Full Text] [Related]  

  • 14. ADHD: monitoring for and managing stimulant adverse effects.
    Mercer M; Farver D
    S D Med; 2013 Dec; 66(12):511, 513. PubMed ID: 24527549
    [No Abstract]   [Full Text] [Related]  

  • 15. Central auditory processing disorder and ADHD.
    Jerome L
    J Am Acad Child Adolesc Psychiatry; 2000 Apr; 39(4):399-400. PubMed ID: 10761339
    [No Abstract]   [Full Text] [Related]  

  • 16. Attention-deficit hyperactivity disorder, methylphenidate, and primary encopresis.
    Golubchik P; Weizman A
    Psychosomatics; 2009; 50(2):178. PubMed ID: 19377031
    [No Abstract]   [Full Text] [Related]  

  • 17. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.
    Kraemer M; Uekermann J; Wiltfang J; Kis B
    Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention deficit hyperactivity disorder and substance use disorders.
    Szobot CM; Bukstein O
    Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):309-23, viii. PubMed ID: 18295148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the medicating ADHD increase or decrease the risk for later substance abuse?
    Wilens TE
    Braz J Psychiatry; 2003 Sep; 25(3):127-8. PubMed ID: 12975683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.